Peptimed Inc., a Jefferson company that is developing novel cancer-fighting drugs, has raised $200,000 of a planned $500,000 funding round, according to a filingwith federal securities regulators.

The company raised the money from one investor, the filing said.

Peptimed was founded in 2012 by Thomas Primiano, who has a Ph.D. in pharmacology from Northwestern University and has been involved with several start-ups. Read the full JSOnline story here.